A vaccine developed by GSK Plc and approved for the prevention of lower respiratory tract disease caused by the respiratory syncytial virus (RSV) appears to have a wider benefit, according to a retrospective study of patients who have received the drug. The study results were presented at a conference in Italy on 17 February. The vaccine, Arexvy, protects against respiratory syncytial virus which causes infections in the lungs and respiratory tract. The virus is common but the effects are most serious for young children and older adults.
